Literature DB >> 20852403

Despite CD4 cell count rebound the higher initial costs of medical care for HIV-infected patients persist 5 years after presentation with CD4 cell counts less than 350 μl.

Hartmut B Krentz1, John Gill.   

Abstract

We determined that for HIV patients presenting with CD4 cell counts less than 350 μl the initial higher costs of care persisted over 5 years. Fifty-nine percent of new patients between 1 April 1998 and 1 April 2003 had CD4 cell counts less than 350 μl. Mean first year total costs ($19 917 $Cdn) were 2.5 times higher than for presentations with CD4 cell counts more than 350 μl ($7840). Total annual costs of care subsequently decreased to $15 663 by year 5, but still remained higher ($8883) than those with CD4 cell counts more than 350 μl despite a median CD4 cell count increase from 134 to 464 μl.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20852403     DOI: 10.1097/QAD.0b013e32833f9e1d

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  13 in total

Review 1.  The impact of HIV-associated anaemia on the incidence of red blood cell transfusion: implications for blood services in HIV-endemic countries.

Authors:  Karin van den Berg; Edward L Murphy; Lelanie Pretorius; Vernon J Louw
Journal:  Transfus Apher Sci       Date:  2014-10-13       Impact factor: 1.764

2.  Cost of human immunodeficiency virus infection in Italy, 2007-2009: effective and expensive, are the new drugs worthwhile?

Authors:  Giuliano Rizzardini; Umberto Restelli; Paolo Bonfanti; Emanuele Porazzi; Elena Ricci; Emanuela Foglia; Laura Carenzi; Davide Croce
Journal:  Clinicoecon Outcomes Res       Date:  2012-09-05

3.  Scaling up antiretroviral treatment services in Karnataka, India: impact on CD4 counts of HIV-infected people.

Authors:  Suresh Shastri; Pavithra Hatna Boregowda; Bharat B Rewari; Sukarma Tanwar; Anita Shet; Ajay M V Kumar
Journal:  PLoS One       Date:  2013-08-08       Impact factor: 3.240

4.  Epidemiological characteristics and predictors of late presentation of HIV infection in Barcelona (Spain) during the period 2001-2009.

Authors:  Patricia Garcia de Olalla; Christian Manzardo; Maria A Sambeat; Inma Ocaña; Hernando Knobel; Victoria Humet; Pere Domingo; Esteve Ribera; Ana Guelar; Andres Marco; Maria J Belza; Josep M Miró; Joan A Caylà
Journal:  AIDS Res Ther       Date:  2011-07-06       Impact factor: 2.250

5.  The Direct Medical Costs of Late Presentation (<350/mm) of HIV Infection over a 15-Year Period.

Authors:  Hartmut B Krentz; M John Gill
Journal:  AIDS Res Treat       Date:  2011-08-29

6.  Cost of HAART in Italy: multicentric evaluation and determinants from a large HIV outpatient cohort.

Authors:  Monica Tontodonati; Giovanni Cenderello; Benedetto Maurizio Celesia; Michele Trezzi; Tamara Ursini; Andrea Costantini; Domenico Marra; Ennio Polilli; Corrado Catalani; Luca Butini; Federica Sozio; Elena Mazzotta; Antonina Sciacca; Giuliano Rizzardini; Lamberto Manzoli; Alessandro Cozzi-Lepri; Giustino Parruti
Journal:  Clinicoecon Outcomes Res       Date:  2014-12-22

7.  Factors associated with presenting late or with advanced HIV disease in the Netherlands, 1996-2014: results from a national observational cohort.

Authors:  Eline L M Op de Coul; Ard van Sighem; Kees Brinkman; Birgit H van Benthem; Marchina E van der Ende; Suzanne Geerlings; Peter Reiss
Journal:  BMJ Open       Date:  2016-01-04       Impact factor: 2.692

8.  Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE).

Authors:  Amanda Mocroft; Jens D Lundgren; Miriam Lewis Sabin; Antonella d'Arminio Monforte; Norbert Brockmeyer; Jordi Casabona; Antonella Castagna; Dominique Costagliola; Francois Dabis; Stéphane De Wit; Gerd Fätkenheuer; Hansjakob Furrer; Anne M Johnson; Marios K Lazanas; Catherine Leport; Santiago Moreno; Niels Obel; Frank A Post; Joanne Reekie; Peter Reiss; Caroline Sabin; Adriane Skaletz-Rorowski; Ignacio Suarez-Lozano; Carlo Torti; Josiane Warszawski; Robert Zangerle; Céline Fabre-Colin; Jesper Kjaer; Genevieve Chene; Jesper Grarup; Ole Kirk
Journal:  PLoS Med       Date:  2013-09-03       Impact factor: 11.069

9.  Establishing a community-based participatory research partnership among people who use drugs in Ottawa: the PROUD cohort study.

Authors:  Lisa Lazarus; Ashley Shaw; Sean LeBlanc; Alana Martin; Zack Marshall; Kristen Weersink; Dolly Lin; Kira Mandryk; Mark W Tyndall
Journal:  Harm Reduct J       Date:  2014-10-13

10.  Advanced HIV disease at presentation to care in Nairobi, Kenya: late diagnosis or delayed linkage to care?--a cross-sectional study.

Authors:  Mia Liisa van der Kop; Lehana Thabane; Patricia Opondo Awiti; Samuel Muhula; Lennie Bazira Kyomuhangi; Richard Todd Lester; Anna Mia Ekström
Journal:  BMC Infect Dis       Date:  2016-04-18       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.